Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data

Ibon Gurruchaga Sotés,M. Carmen Gómez-Mateo,María Eugenia Ortega Izquierdo,Javier Martínez-Trufero

DOI: https://doi.org/10.3390/cancers16020267

2024-01-09

Cancers

Abstract:Background: The combination of gemcitabine and dacarbazine has exhibited efficacy in terms of progression-free survival (PFS) and overall survival (OS) for aSTSs, albeit without robust confirmation from larger clinical trials. Methods: We conducted a retrospective study in a single institution involving aSTS patients treated with gemcitabine and dacarbazine. Results: 95 patients were assessed, pointing to a benefit in PFS of 3.5 months and an OS of 14.2 months. Patients with translocated histotypes had better PFS, while those with platelet–lymphocyte ratios (PLRs) surpassing a specific threshold or lower albumin levels had poorer overall survival. Conclusions: This study validates previous findings from three phase I–II trials, affirming the utility of this treatment approach in routine clinical practice.

oncology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the practical application effects of the combined treatment of gemcitabine and dacarbazine in advanced soft - tissue sarcomas (aSTSs). Specifically, the research objectives include:

1. **Verify clinical trial results**: Verify the efficacy of the combined treatment of gemcitabine and dacarbazine in terms of progression - free survival (PFS) and overall survival (OS) reported in the previous three phase I - II clinical trials through real - world data.
2. **Evaluate treatment effects**: Determine the clinical benefits of the combined treatment regimen in actual clinical practice, including disease control rate (DCR), PFS and OS.
3. **Identify prognostic and predictive factors**: Analyze clinical and biological factors that may affect treatment outcomes, such as platelet - lymphocyte ratio (PLR), albumin level, etc., to help doctors select the most appropriate treatment regimen.

### Research background

- **Advanced soft - tissue sarcomas (aSTSs)**: Due to their low incidence, these tumors are classified as rare diseases by the World Health Organization (WHO). Limited treatment options and insufficient investment in major research institutions lead to highly inconsistent treatment responses.
- **Existing treatment regimens**: Standard first - line treatment usually uses anthracycline chemotherapy drugs, such as doxorubicin monotherapy. Second - line treatment selects different treatment regimens according to the pathological type, but lacks large - scale clinical trials to confirm its effectiveness.
- **Combined treatment of gemcitabine and dacarbazine**: In three phase I - II clinical trials, this combined treatment has shown significant advantages in PFS and OS, but more real - world data are needed to verify its effect in routine clinical practice.

### Research methods

- **Retrospective study**: Data of 95 aSTSs patients who received the combined treatment of gemcitabine and dacarbazine were collected in a single institution.
- **Primary objective**: Evaluate the clinical benefits of the combined treatment regimen, including DCR and PFS.
- **Secondary objective**: Evaluate OS, analyze clinicopathological features, and identify toxicity and biological prognostic factors related to treatment outcomes.

### Results

- **Treatment effects**:
- The median PFS was 3.5 months.
- The median OS was 14.2 months.
- The objective response rate (ORR) was 22% and the disease - stable rate (SD) was 30.5%.
- **Prognostic and predictive factors**:
- Univariate analysis showed that leiomyosarcoma (LMS) pathological type, molecular complexity, translocation subtype, single - lung metastasis and partial or complete response (PR or CR) were significant prognostic markers for PFS.
- Multivariate COX regression analysis showed that translocation subtype (p = 0.036) and objective response (p < 0.000) were independent prognostic markers for PFS.
- For OS, baseline lymphocyte count less than 1000 cells/mm³, each unit increase in baseline albumin concentration, each unit increase in red blood cell distribution width (RDW) at the end of treatment, pre - treatment PLR exceeding 190, and objective response were all independent prognostic markers.

### Discussion

- **Clinical significance**: This study is the first to verify the survival benefit of the combined treatment of gemcitabine and dacarbazine in non - selected aSTSs patients through real - world data, providing an important reference for clinical practice.
- **Comparison with other studies**: The research results are similar to those of previous clinical trials, further supporting the effectiveness and safety of this combined treatment.
- **Future directions**: Although this combined treatment has been widely accepted in some European countries such as Spain, more research is still needed to further verify its effect in different populations and explore more effective individualized treatment strategies.

Through these research results, the paper provides new insights into the treatment of advanced soft - tissue sarcomas and a basis for clinicians to select the best treatment regimens.